- Home
- BDTX vs FITBO Comparison
BDTX vs FITBO Comparison
Compare BDTX & FITBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | FITBO |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | 18676 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | N/A |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDTX | FITBO |
|---|---|---|
| Price | $1.99 | $18.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 19.9K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $18.23 |
| 52 Week High | $4.94 | $21.40 |
Technical Indicators
Market Signals| Indicator | BDTX | FITBO |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 31.24 |
| Support Level | N/A | N/A |
| Resistance Level | $2.30 | $18.76 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 0.75 | 25.48 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About FITBO Fifth Third Bancorp Depositary Shares each representing a 1/1000th ownership interest in a share of Non-Cumulative Perpetual Preferred Stock Series K
Fifth Third Bancorp is a midsize regional bank in the US, with total assets of around $300 billion as of March 2026. The bank closed its acquisition of Comercia in February 2026. Headquartered in Cincinnati, Ohio, Fifth Third has a strong presence in the US Midwest and is currently expanding in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and Treasury management, wealth and asset management, and capital markets.